"The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker. Lilly said Thursday that its top-selling drugs, Mounjaro and Zepbound, brought in more than $10 billion combined during the recently completed third quarter. That made up over half of the drugmaker's $17.6 billion in total sales."
"Popular treatments labeled GLP-1 receptor agonists are fueling the soaring sales and deal interest. They work by mimicking hormones in the gut and the brain to regulate appetite and feelings of fullness. But they don't work for everyone and can produce side effects that include nausea and stomach pain. Supplies of the drugs have improved this year, and some insurance coverage is growing. That helps improve access to drugs that can cost around $500 a month without coverage."
"The treatments are injectable drugs, but Novo and Lilly are also developing easier-to-take pill versions. U.S. sales of Lilly's weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, revenue from the diabetes drug Mounjaro, which has been on the market longer, has doubled, to $6.52 billion, thanks to growth outside the U.S. Combined, the drugs have brought in nearly $25 billion in sales so far this year for Indianapolis-based Lilly. That surpasses the entire company's revenue total from 2020."
Eli Lilly's top-selling GLP-1 drugs Mounjaro and Zepbound produced more than $10 billion in the third quarter, accounting for over half of the company's $17.6 billion in sales and helping drive a $5.58 billion quarterly profit. Combined sales of those drugs reached nearly $25 billion so far this year, exceeding the company's total revenue from 2020. Novo Nordisk moved to acquire Metsera amid competing bids as demand for obesity and diabetes treatments surges. GLP-1 receptor agonists mimic gut and brain hormones to regulate appetite, can cause nausea and stomach pain, and remain costly without insurance coverage.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]